帕金森病是否与全髋关节置换术后死亡率增加、预后评分较差和翻修风险相关?来自瑞典髋关节置换登记处的研究发现
基于瑞典髋关节置换登记处与行政健康数据库的匹配队列研究,纳入1999年1月1日至2012年12月31日因原发性骨关节炎行全髋关节置换术的帕金森病患者490例,按年龄、性别、Charlson合并症指数、手术入路和固定方式1:1精确匹配对照组。结果显示帕金森病患者90天和1年死亡率无差异,9年死亡率升高;1年和9年翻修风险升高;1年疼痛缓解无差异,但生活质量和总体健康评分改善较小。
要点
- 帕金森病患者全髋关节置换术后90天和1年死亡风险与匹配对照组无差异。
- 帕金森病患者9年死亡风险高于对照组(54.35% vs 28.05%)。
- 帕金森病患者1年和9年翻修风险均高于对照组。
核心结论
- 帕金森病与翻修风险增加相关,但与评估全髋关节置换术前风险获益相关的短期死亡率无关。
- 鉴于长期死亡风险升高更可能归因于进行性神经系统疾病而非全髋关节置换术本身,且帕金森病患者报告的结局与对照组相当,传统上不愿对帕金森病患者行全髋关节置换术可能过于保守。
- 需要对其他神经系统疾病患者全髋关节置换术的结局进行进一步研究,以更好地探讨这一传统教学背后的更广泛假设。
研究设计与样本
- 数据来源于瑞典髋关节置换登记处与行政健康数据库合并的数据库。
- 纳入1999年1月1日至2012年12月31日因原发性骨关节炎行全髋关节置换术的所有帕金森病患者,应用排除标准后n=490。
- 对照组通过年龄、性别、Charlson合并症指数、手术入路和固定方式进行精确一对一匹配生成。
- 采用Kaplan-Meier法和log-rank检验比较两组死亡风险和翻修风险;患者报告结局指标(PROMs)常规记录为EQ-5D、EQ VAS和疼痛VAS,在术前访视和术后1年测量,比较两组PROM评分的平均绝对值及评分随时间的变化。
- 证据等级为III级,治疗性研究。
主要发现
- 90天死亡风险对照组=0.61%(95%CI=0.00-1.3),帕金森病组=0.62%(95%CI=0.00-1.31),p=0.998;1年死亡风险对照组=2.11%(95%CI=0.81-3.39),帕金森病组=2.56%(95%CI=1.12-3.97),p=0.670。
- 9年死亡风险帕金森病组高于对照组(对照组=28.05%,95%CI=22.29-33.38;帕金森病组=54.35%,95%CI=46.72-60.88;p<0.001)。
- 90天翻修风险对照组=0.41%(95%CI=0.00-0.98),帕金森病组=1.03%(95%CI=0.13-1.92),p=0.256;1年翻修风险帕金森病组高于对照组(对照组=0.41%,95%CI=0.00-0.98;帕金森病组=2.10%,95%CI=0.80-3.38;p=0.021)。
- 采用Kaplan-Meier法,9年翻修风险帕金森病组高于对照组(对照组=1.75%,95%CI=0.11-3.36;帕金森病组=5.44%,95%CI=2.89-7.91;p=0.001)。
- 术后1年疼痛缓解程度两组无差异(疼痛VAS评分平均降低值对照组=48.85,SD=20.46;帕金森病组=47.18,SD=23.96;p=0.510)。
临床怎么用
- 作者认为,鉴于长期死亡风险升高更可能归因于进行性神经系统疾病而非全髋关节置换术本身,且帕金森病患者报告的结局与对照组相当,传统上不愿对帕金森病患者行全髋关节置换术可能过于保守。
- 作者认为,需要对其他神经系统疾病患者全髋关节置换术的结局进行进一步研究,以更好地探讨这一传统教学背后的更广泛假设。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurological conditions such as Parkinson's disease are commonly accepted as a risk factor for an increased likelihood of undergoing revision surgery or death after THA. However, the available evidence for an association between Parkinson's disease and serious complications or poorer patient-reported outcomes after THA is limited and contradictory. QUESTIONS/PURPOSES: (1) Do patients with a preoperative diagnosis of Parkinson's disease have an increased risk of death after elective THA compared with a matched control group of patients? (2) After matching for patient- and surgery-related factors, do revision rates differ between the patients with Parkinson's disease and the matched control group? (3) Are there any differences in patient-reported outcome measures for patients with Parkinson's disease compared with the matched control group? METHODS: Data were derived from a merged database with information from the Swedish Hip Arthroplasty Register and administrative health databases. We identified all patients with Parkinson's disease who underwent THA for primary osteoarthritis between January 1, 1999 and December 31, 2012 (n = 490 after exclusion criteria applied). A control group was generated through exact one-to-one matching for age, sex, Charlson comorbidity index, surgical approach, and fixation method. Risk of death and revision were compared between the groups using Kaplan-Meier and log-rank testing. Patient-reported outcome measures (PROMs), routinely recorded as EQ-5D, EQ VAS, and pain VAS, were measured at the preoperative visit and at 1-year postoperatively; mean absolute values for PROM scores and change in scores over time were compared between the two groups. RESULTS: The risk of death did not differ at 90 days (control group risk = 0.61%; 95% CI = 0.00-1.3; Parkinson's disease group risk = 0.62%; 95% CI = 0.00-1.31; p = 0.998) or 1 year (control group = 2.11%; 95% CI = 0.81-3.39; Parkinson's disease group = 2.56%, 95% CI = 1.12-3.97; p = 0.670). At 9 years, the risk of death was increased for patients with Parkinson's disease (control group = 28.05%; 95% CI = 22.29-33.38; Parkinson's disease group = 54.35%; 95% CI = 46.72-60.88; p < 0.001). The risk of revision did not differ at 90 days (control group = 0.41%; 95% CI = 0.00-0.98; Parkinson's disease group = 1.03%; 95% CI = 0.13-1.92; p = 0.256). At 1 year, the risk of revision was higher for patients with Parkinson's disease (control group = 0.41%; 95% CI = 0.00-0.98; Parkinson's disease group = 2.10%; 95% CIs = 0.80-3.38; p = 0.021). This difference was more pronounced at 9 years (control group = 1.75%; 95% CI = 0.11-3.36; Parkinson's disease group = 5.44%; 95% CI = 2.89-7.91; p = 0.001) when using the Kaplan-Meier method. There was no difference between the control and Parkinson's disease groups for level of pain relief at 1 year postoperatively (mean reduction in pain VAS score for control group = 48.85, SD = 20.46; Parkinson's disease group = 47.18, SD = 23.96; p = 0.510). Mean change in scores for quality of life and overall health from preoperative measures to 1 year postoperatively were smaller for patients in the Parkinson's disease group compared with controls (mean change in EQ-5D scores for control group = 0.42, SD = 0.32; Parkinson's disease group = 0.30, SD = 0.37; p 0.003; mean change in EQ VAS scores for control group = 20.94, SD = 23.63; Parkinson's disease = 15.04, SD = 23.00; p = 0.027). CONCLUSIONS: Parkinson's disease is associated with an increased revision risk but not with short-term mortality rates relevant to assessing risk versus benefit before undergoing THR. The traditional reluctance to perform THR in patients with Parkinson's disease may be too conservative given that the higher long-term risk of death is more likely due to the progressive neurological disorder and not THR itself, and patients with Parkinson's disease report comparable outcomes to controls. Further research on outcomes in THR for patients with other neurological conditions is needed to better address the broader assumptions underlying this traditional teaching.Level of Evidence Level III, therapeutic study.
引用
- Wojtowicz AL, Mohaddes M, Odin D, et al. Is Parkinson's Disease Associated with Increased Mortality, Poorer Outcomes Scores, and Revision Risk After THA? Findings from the Swedish Hip Arthroplasty Register. Clin Orthop Relat Res. 2019. PMID: 31136433. doi:10.1097/CORR.0000000000000679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。